Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Authors: Carol Moreno, Richard Greil, Fatih Demırkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Šimkovič, Olga Samoilova, Jan Novák, Dina Ben‐Yehuda, Владимир Стругов, Devinder Gill, John G. Gribben, Emily Hsu, Chih‐Jian Lih, Cathy Zhou, Fong Clow, Danelle F. James, Lori Styles, Ian W. Flinn - The Lancet 2018 cited by 548